Health Care [ 11/12 ] | Health Care Technology [ 63/75 ]
NASDAQ | Common Stock
Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally.
The company offers solutions to healthcare providers, comprising Practice Management software, AI Patient Scheduling Software, and Electronic Statements and Payments; revenue cycle management solutions, including Revenue Cycle Services and revenue cycle management clearinghouse; electronic health records solutions, which include ePrescribe with EPCS, EHR software, Veradigm HER, and Practice Fusion HER; and Patient Engagement Platform.
It also provides solutions to network partners, which comprise API connectivity solutions, such as Veradigm Connect, Veradigm App Expo, and Diagnostic Ordering and Resulting Network; Channel Partner Program; and Veradigm ePrescribe Enterprise.
In addition, the company offers solutions to health plans and payers, comprising risk adjustment solutions, such as Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics; quality management solutions, which include quality analytics and risk adjustment and quality management; data exchange+coding solutions, including eChart Courier, eChart Coder, and eChart Integration and Analytics; provider engagement and Veradigm Payer Insights; and Veradigm Payerpath solutions.
Further, it provides solutions to biophama, including real world data solutions, such as real world and health data sets and cardiology and metabolic registries; real world evidence and Real World Evidence Analytics Platform; therapy focused solutions, such as cardiovascular, central nervous system, metabolic, and immunology data; and Digital Health Media solutions.
The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023.
Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 3, 24 | 0.00 Decreased by -100.00% | 0.54 Decreased by -100.00% |
| Mar 13, 24 | 0.00 Decreased by -100.00% | 0.33 Decreased by -100.00% |
| Oct 20, 23 | 0.21 Decreased by -6.52% | 0.28 Decreased by -23.32% |
| Sep 29, 23 | 0.26 Increased by +46.11% | 0.20 Increased by +28.80% |
| May 10, 23 | 0.16 Increased by +23.08% | 0.27 Decreased by -40.74% |
| Mar 1, 23 | 0.27 Decreased by -65.82% | 0.27 |
| Nov 3, 22 | 0.23 Decreased by -14.81% | 0.19 Increased by +21.05% |
| Aug 4, 22 | 0.18 Decreased by -21.74% | 0.15 Increased by +20.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | 151.90 M Decreased by -58.86% | 11.00 M Decreased by -31.68% | Increased by +7.24% Increased by +66.06% |
| Jun 30, 22 | 150.90 M Decreased by -59.62% | 3.20 M Decreased by -85.41% | Increased by +2.12% Decreased by -63.86% |
| Mar 31, 22 | 142.70 M Decreased by -61.26% | 22.90 M Increased by +152.84% | Increased by +16.05% Increased by +552.66% |
| Dec 31, 21 | 391.70 M Increased by +41.03% | 87.30 M Decreased by -88.01% | Increased by +22.29% Decreased by -91.50% |
| Sep 30, 21 | 369.20 M Decreased by -8.18% | 16.10 M Increased by +3.12 K% | Increased by +4.36% Increased by +3.41 K% |
| Jun 30, 21 | 373.71 M Decreased by -8.00% | 21.93 M Increased by +388.31% | Increased by +5.87% Increased by +413.39% |
| Mar 31, 21 | 368.35 M Decreased by -11.60% | 9.06 M Increased by +144.40% | Increased by +2.46% Increased by +150.22% |
| Dec 31, 20 | 277.73 M Decreased by -38.42% | 727.82 M Increased by +3.93 K% | Increased by +262.06% Increased by +6.32 K% |